{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:13:27Z","timestamp":1761167607524,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.ghir.2004.03.039","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T06:36:08Z","timestamp":1084257368000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["The place of pegvisomant in the acromegaly treatment algorithm"],"prefix":"10.1016","volume":"14","author":[{"given":"Angela N","family":"Paisley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Trainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2004.03.039_BIB1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","article-title":"Determinants of clinical outcome and survival in acromegaly","volume":"41","author":"Rajasoorya","year":"1994","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2004.03.039_BIB2","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly","volume":"86","author":"Bates","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ghir.2004.03.039_BIB3","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jcem.83.10.5111","article-title":"Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results","volume":"83","author":"Abosch","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB4","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB5","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB6","first-page":"526","article-title":"Criteria for cure of acromegaly: a consensus statement","volume":"85","author":"Giustina","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB7","first-page":"3534","article-title":"Acromegaly-consensus, what consensus?","volume":"87","author":"Trainer","year":"2002","journal-title":"J Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB8","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible? Effect of a 5-year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance","volume":"86","author":"Colao","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3171\/jns.1998.89.3.0353","article-title":"Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly","volume":"89","author":"Freda","year":"1988","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ghir.2004.03.039_BIB10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2265.1996.8370847.x","article-title":"Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure","volume":"45","author":"Sheaves","year":"1996","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.ghir.2004.03.039_BIB11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/qjmed\/92.12.741","article-title":"Outcome of surgery for acromegaly \u2013 the experience of a dedicated pituitary surgeon","volume":"92","author":"Gittoes","year":"1999","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ghir.2004.03.039_BIB12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2265.1999.00760.x","article-title":"Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience","volume":"50","author":"Ahmed","year":"1999","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.ghir.2004.03.039_BIB13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.bja.a013400","article-title":"Anaesthetic complications of acromegaly","volume":"84","author":"Seidman","year":"2000","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ghir.2004.03.039_BIB14","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1210\/jc.2002-020072","article-title":"The role of pharmacotherapy in perioperative management of patients with acromegaly","volume":"88","author":"Ben-Shlomo","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB16","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1210\/jcem.85.7.6699","article-title":"Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8529(18)30210-X","article-title":"Treatment of acromegaly with dopamine agonists","volume":"21","author":"Jaffe","year":"1992","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.ghir.2004.03.039_BIB18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB19","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB20","first-page":"3267","article-title":"Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly","volume":"80","author":"Stewart","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1991.00400080073013","article-title":"Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group","volume":"151","author":"Vance","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ghir.2004.03.039_BIB22","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicentre study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumour size","volume":"87","author":"Bevan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB23","doi-asserted-by":"crossref","unstructured":"I. Lancranjan, A. Brew Atkinson, the Sandostatin LAR Group, Results of a European multicentre study with Sandostatin LAR in acromegalic patients, Pituitary 1 (1999) 105\u2013114","DOI":"10.1023\/A:1009980404404"},{"key":"10.1016\/j.ghir.2004.03.039_BIB24","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1210\/jcem.80.9.7673422","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients \u2013 a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB25","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1210\/jc.2001-011913","article-title":"Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly","volume":"87","author":"Ayuk","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB26","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2004.03.039_BIB27","unstructured":"A.J. van der Lely, S.W.J. Lamberts, A. Barker, in: 80th Annual Meeting of the Endocrine Society, New Orleans, LA, 1998 (Abstract OR4-1)"},{"key":"10.1016\/j.ghir.2004.03.039_BIB28","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ghir.2004.03.039_BIB29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","article-title":"Growth hormone receptor antagonist improves insulin resistance in acromegaly","volume":"12","author":"Rose","year":"2002","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.ghir.2004.03.039_BIB30","unstructured":"D. Clemmons, A. Barkan, S. Melmed, J.P. Monson, W.M. Drake, K.E. Friend, P. Burman, Pegvisomant improves glucose homeostasis in patients with acromegaly previously treated with octreotide LAR, in: 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, 2003, P2-341"},{"key":"10.1016\/j.ghir.2004.03.039_BIB31","doi-asserted-by":"crossref","unstructured":"W.M. Drake, S.V. Rowles, M.E. Roberts, F.K. Fode, M. Besser, J.P Monson, P.J. Trainer, Improvement in insulin sensitivity in patients with acromegaly converted from depot octreotide (Sandostatin LAR) to pegvisomant, in: 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, 2003, P1-633","DOI":"10.1530\/eje.0.1490521"},{"key":"10.1016\/j.ghir.2004.03.039_BIB32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","article-title":"Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly","volume":"56","author":"Parkinson","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2004.03.039_BIB33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2265.1994.tb01830.x","article-title":"The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults","volume":"41","author":"Weaver","year":"1994","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2004.03.039_BIB34","first-page":"2989","article-title":"Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly","volume":"86","author":"Trainer","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1210\/jcem.86.2.7206","article-title":"Control of tumour size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient","volume":"86","author":"van der Lely","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2004.03.039_BIB36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocrine Rev."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109663740400070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109663740400070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:41:01Z","timestamp":1761086461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109663740400070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":36,"alternative-id":["S109663740400070X"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2004.03.039","relation":{},"ISSN":["1096-6374"],"issn-type":[{"type":"print","value":"1096-6374"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The place of pegvisomant in the acromegaly treatment algorithm","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2004.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}